Results 211 to 220 of about 55,731 (254)

Muscle wasting in cancer

Current Opinion in Clinical Nutrition and Metabolic Care, 2015
The aim of the present review is to examine the impact of mitochondrial dysfunction in cancer cachexia.Oxidative pathways are altered in this tissue during muscle wasting and this seems to be a consequence of mitochondrial abnormalities that include altered morphology and function, decreased ATP synthesis and uncoupling.An alteration of energy balance ...
Josep M, Argilés, Francisco J, López-Soriano, Silvia, Busquets   +2 more
openaire   +2 more sources

Muscle wasting in cardiac cachexia

The International Journal of Biochemistry & Cell Biology, 2005
Cardiac cachexia is a serious complication of chronic heart failure which is characterized by complex changes that overall lead to a catabolic/anabolic imbalance resulting in body wasting and a poor prognosis. The wasting process affects all body components, but particularly the skeletal musculature, causing extreme fatigue and weakness, especially in ...
Strassburg, Sabine, Springer, Jochen, Anker, Stefan D.   +2 more
openaire   +3 more sources

Fixing Wasting Muscles

Scientific American, 2018
The article discusses the use of the gene editing technique CRISPR/Cas9 to increase dystrophin as a way to treat dogs with duchenne muscular dystrophy, referencing a study coauthored by molecular biologist Eric Olson in the "Science" journal.
openaire   +2 more sources

Sex Differences in Muscle Wasting

2017
With aging and other muscle wasting diseases, men and women undergo similar pathological changes in skeletal muscle: increased inflammation, enhanced oxidative stress, mitochondrial dysfunction, satellite cell senescence, elevated apoptosis and proteasome activity, and suppressed protein synthesis and myocyte regeneration.
Lindsey J, Anderson, Haiming, Liu, Jose M, Garcia   +2 more
openaire   +2 more sources

Muscle type and fiber type specificity in muscle wasting

The International Journal of Biochemistry & Cell Biology, 2013
Muscle wasting occurs in a variety of conditions, including both genetic diseases, such as muscular dystrophies, and acquired disorders, ranging from muscle disuse to cancer cachexia, from heart failure to aging sarcopenia. In most of these conditions, the loss of muscle tissue is not homogeneous, but involves specific muscle groups, for example ...
CICILIOT, STEFANO, Rossi A, Dyar KA, BLAAUW, BERT, Schiaffino S.   +4 more
openaire   +4 more sources

Muscle wasting in chronic kidney disease

Pediatric Nephrology, 2017
Loss of lean body mass is a relevant component of the cachexia, or protein energy wasting (PEW), syndrome. Reduced muscle mass seems to be the most solid criterion for the presence of cachexia/PEW in patients with chronic kidney disease (CKD), and those with greater muscle mass loss have a higher risk of death.
Eduardo A. Oliveira, Wai W. Cheung, Kalodiah G. Toma, Robert H. Mak   +3 more
openaire   +2 more sources

Therapeutic approaches for muscle wasting disorders

Pharmacology & Therapeutics, 2007
Muscle wasting and weakness are common in many disease states and conditions including aging, cancer cachexia, sepsis, denervation, disuse, inactivity, burns, HIV-acquired immunodeficiency syndrome (AIDS), chronic kidney or heart failure, unloading/microgravity, and muscular dystrophies.
Gordon S, Lynch, Jonathan D, Schertzer, James G, Ryall   +2 more
openaire   +2 more sources

Drugs of Muscle Wasting and Their Therapeutic Targets

2018
Muscle wasting and weakness such as cachexia, atrophy, and sarcopenia are characterized by marked decreases in the protein content, myonuclear number, muscle fiber size, and muscle strength. This chapter focuses on the recent advances of pharmacological approach for attenuating muscle wasting.A myostatin-inhibiting approach is very intriguing to ...
Kunihiro, Sakuma, Akihiko, Yamaguchi
openaire   +2 more sources

Muscle wasting

Current Opinion in Clinical Nutrition and Metabolic Care, 2014
Cirrhosis is the result of the progression of necroinflammatory liver diseases leading to fibrosis, portal hypertension, and a catabolic state, which might cause muscle wasting or sarcopenia. In this review, we analyze the methods for muscularity assessment, the incidence and clinical impact of muscle wasting, and potential novel therapeutic strategies
openaire   +2 more sources

Muscle Wasting

2012
Denis D. Bensard, Philip F. Stahel, Jorge Cerdá, Babak Sarani, Sajid Shahul, Daniel Talmor, Peter M. Hammer, C. William Schwab, Steven Reynolds, Omar Ahmad, Tsuyoshi Kaneko, Anthony L. Estrera, William A. Knight, Bradley P. Dixon, Richard L. Gamelli, Joseph A. Posluszny, Mansoor N. Bangash, Rupert M. Pearse, Albert J. Ruggieri, Richard J. Levy, Clifford S. Deutschman, Clifford S. Deutschman, Richard J. Levy, Prasanna Simha Mohan Rao, John P. Kress, Sabino Scolletta, Norman E. McSwain, Jeffry L. Kashuk, Angela Sauaia, Ernest E. Moore, Per-Olof J. Hasselgren, Wade R. Smith, John T. Riehl, Denis D. Bensard, Philip F. Stahel, Berton R. Moed, B. Kirke Bieneman, Berton R. Moed, Clay C. Cothren, Ernest E. Moore, Nima Majlesi, Richard D. Shih, Eelco F. M. Wijdicks, Melissa Nyendak, Tarek Eid, Payam Nahid, Kevin Winthrop, David Lewinsohn, Julie P. Chou, Tom Lim, Andrew G. Lee, Christopher H. Mody, Tom Lim, Julie P. Chou, Christopher H. Mody, Nathan T. Mowery, Alexander L. Colonna, J. Wayne Meredith, Alain Combes, Jonathan R. Egan, Marino S. Festa, A. Montcriol, Y. Asencio, F. Kerbaul   +63 more
  +4 more sources